3e6i Citations

Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates.

J Biol Chem 283 33698-707 (2008)
Cited: 116 times
EuropePMC logo PMID: 18818195

Abstract

Human microsomal cytochrome P-450 2E1 (CYP2E1) monooxygenates > 70 low molecular weight xenobiotic compounds, as well as much larger endogenous fatty acid signaling molecules such as arachidonic acid. In the process, CYP2E1 can generate toxic or carcinogenic compounds, as occurs with acetaminophen overdose, nitrosamines in cigarette smoke, and reactive oxygen species from uncoupled catalysis. Thus, the diverse roles that CYP2E1 has in normal physiology, toxicity, and drug metabolism are related to its ability to metabolize diverse classes of ligands, but the structural basis for this was previously unknown. Structures of human CYP2E1 have been solved to 2.2 angstroms for an indazole complex and 2.6 angstroms for a 4-methylpyrazole complex. Both inhibitors bind to the heme iron and hydrogen bond to Thr303 within the active site. Complementing its small molecular weight substrates, the hydrophobic CYP2E1 active site is the smallest yet observed for a human cytochrome P-450. The CYP2E1 active site also has two adjacent voids: one enclosed above the I helix and the other forming a channel to the protein surface. Minor repositioning of the Phe478 aromatic ring that separates the active site and access channel would allow the carboxylate of fatty acid substrates to interact with conserved 216QXXNN220 residues in the access channel while positioning the hydrocarbon terminus in the active site, consistent with experimentally observed omega-1 hydroxylation of saturated fatty acids. Thus, these structures provide insights into the ability of CYP2E1 to effectively bind and metabolize both small molecule substrates and fatty acids.

Reviews - 3e6i mentioned but not cited (2)

  1. Recent Structural Insights into Cytochrome P450 Function. Guengerich FP, Waterman MR, Egli M. Trends Pharmacol Sci 37 625-640 (2016)
  2. Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR. Gay SC, Roberts AG, Halpert JR. Future Med Chem 2 1451-1468 (2010)

Articles - 3e6i mentioned but not cited (16)

  1. Structures of human cytochrome P-450 2E1. Insights into the binding of inhibitors and both small molecular weight and fatty acid substrates. Porubsky PR, Meneely KM, Scott EE. J Biol Chem 283 33698-33707 (2008)
  2. Herbivore-induced and floral homoterpene volatiles are biosynthesized by a single P450 enzyme (CYP82G1) in Arabidopsis. Lee S, Badieyan S, Bevan DR, Herde M, Gatz C, Tholl D. Proc Natl Acad Sci U S A 107 21205-21210 (2010)
  3. Human cytochrome P450 2E1 structures with fatty acid analogs reveal a previously unobserved binding mode. Porubsky PR, Battaile KP, Scott EE. J Biol Chem 285 22282-22290 (2010)
  4. Phylogenomics of the benzoxazinoid biosynthetic pathway of Poaceae: gene duplications and origin of the Bx cluster. Dutartre L, Hilliou F, Feyereisen R. BMC Evol Biol 12 64 (2012)
  5. Structural comparison of cytochromes P450 2A6, 2A13, and 2E1 with pilocarpine. DeVore NM, Meneely KM, Bart AG, Stephens ES, Battaile KP, Scott EE. FEBS J 279 1621-1631 (2012)
  6. Investigation of indazole unbinding pathways in CYP2E1 by molecular dynamics simulations. Shen Z, Cheng F, Cheng F, Xu Y, Fu J, Xiao W, Shen J, Liu G, Li W, Tang Y. PLoS One 7 e33500 (2012)
  7. Drug targeting CYP2E1 for the treatment of early-stage alcoholic steatohepatitis. Diesinger T, Buko V, Lautwein A, Dvorsky R, Belonovskaya E, Lukivskaya O, Naruta E, Kirko S, Andreev V, Buckert D, Bergler S, Renz C, Schneider E, Kuchenbauer F, Kumar M, Günes C, Büchele B, Simmet T, Müller-Enoch D, Wirth T, Haehner T. PLoS One 15 e0235990 (2020)
  8. Network pharmacology-based antioxidant effect study of zhi-zi-da-huang decoction for alcoholic liver disease. An L, Feng F. Evid Based Complement Alternat Med 2015 492470 (2015)
  9. Combined Linear Interaction Energy and Alchemical Solvation Free-Energy Approach for Protein-Binding Affinity Computation. Rifai EA, Ferrario V, Pleiss J, Geerke DP. J Chem Theory Comput 16 1300-1310 (2020)
  10. Functioning of drug-metabolizing microsomal cytochrome P450s: In silico probing of proteins suggests that the distal heme 'active site' pocket plays a relatively 'passive role' in some enzyme-substrate interactions. Venkatachalam A, Parashar A, Manoj KM. In Silico Pharmacol 4 2 (2016)
  11. Inhibition of human cytochrome P450 2E1 and 2A6 by aldehydes: structure and activity relationships. Kandagatla SK, Mack T, Simpson S, Sollenberger J, Helton E, Raner GM. Chem Biol Interact 219 195-202 (2014)
  12. A practical strategy to develop isoform-selective near-infrared fluorescent probes for human cytochrome P450 enzymes. Feng L, Tian X, Yao D, Yu Z, Huo X, Tian Z, Ning J, Cui J, James TD, Ma X. Acta Pharm Sin B 12 1976-1986 (2022)
  13. Integrated Metabolomics and Network Pharmacology to Reveal the Mechanisms of Gandouling Tablets Against Copper-Overload-Induced Neuronal Injury in Rats with Wilson's Disease. Chen L, Xu WY, Chen H, Han YQ, Zhang YT. Drug Des Devel Ther 17 1763-1782 (2023)
  14. Phenylalanine Residues in the Active Site of CYP2E1 Participate in Determining the Binding Orientation and Metabolism-Dependent Genotoxicity of Aromatic Compounds. Hu K, Tu H, Xie J, Yang Z, Li Z, Chen Y, Liu Y. Toxics 11 495 (2023)
  15. Rhoifolin Alleviates Alcoholic Liver Disease In Vivo and In Vitro via Inhibition of the TLR4/NF-κB Signaling Pathway. Mai B, Han L, Zhong J, Shu J, Cao Z, Fang J, Zhang X, Gao Z, Xiao F. Front Pharmacol 13 878898 (2022)
  16. Taming Food-Drug Interaction Risk: Potential Inhibitory Effects of Citrus Juices on Cytochrome Liver Enzymes Can Safeguard the Liver from Overdose Paracetamol-Induced Hepatotoxicity. Shalaby AS, Eid HH, El-Shiekh RA, Mohamed OG, Tripathi A, Al-Karmalawy AA, Sleem AA, Morsy FA, Ibrahim KM, Tadros SH, Youssef FS. ACS Omega 8 26444-26457 (2023)


Reviews citing this publication (19)

  1. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Zhou SF, Wang B, Yang LP, Liu JP. Drug Metab Rev 42 268-354 (2010)
  2. Role of Cytochrome P450 2C8 in Drug Metabolism and Interactions. Backman JT, Filppula AM, Niemi M, Neuvonen PJ. Pharmacol Rev 68 168-241 (2016)
  3. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Wang B, Yang LP, Zhang XZ, Huang SQ, Bartlam M, Zhou SF. Drug Metab Rev 41 573-643 (2009)
  4. Conformational plasticity and structure/function relationships in cytochromes P450. Pochapsky TC, Kazanis S, Dang M. Antioxid Redox Signal 13 1273-1296 (2010)
  5. Structural diversity of eukaryotic membrane cytochrome p450s. Johnson EF, Stout CD. J Biol Chem 288 17082-17090 (2013)
  6. Cytosolic nucleic acid sensors and innate immune regulation. Ori D, Murase M, Kawai T. Int Rev Immunol 36 74-88 (2017)
  7. Conformational diversity and ligand tunnels of mammalian cytochrome P450s. Yu X, Cojocaru V, Wade RC. Biotechnol Appl Biochem 60 134-145 (2013)
  8. Cytochrome P450 2E1 and its roles in disease. Guengerich FP. Chem Biol Interact 322 109056 (2020)
  9. CYP2E1 in Alcoholic and Non-Alcoholic Liver Injury. Roles of ROS, Reactive Intermediates and Lipid Overload. Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. Int J Mol Sci 22 8221 (2021)
  10. Diallyl Sulfide: Potential Use in Novel Therapeutic Interventions in Alcohol, Drugs, and Disease Mediated Cellular Toxicity by Targeting Cytochrome P450 2E1. Rao PS, Midde NM, Miller DD, Chauhan S, Kumar A, Kumar S. Curr Drug Metab 16 486-503 (2015)
  11. Roles of Cytochrome P450 in Metabolism of Ethanol and Carcinogens. Peter Guengerich F, Avadhani NG. Adv Exp Med Biol 1032 15-35 (2018)
  12. Suppressive and pro-inflammatory roles for IL-4 in the pathogenesis of experimental drug-induced liver injury: a review. Njoku DB. Expert Opin Drug Metab Toxicol 6 519-531 (2010)
  13. Modeling of interactions between xenobiotics and cytochrome P450 (CYP) enzymes. Raunio H, Kuusisto M, Juvonen RO, Pentikäinen OT. Front Pharmacol 6 123 (2015)
  14. Cytochrome P450 endoplasmic reticulum-associated degradation (ERAD): therapeutic and pathophysiological implications. Kwon D, Kim SM, Correia MA. Acta Pharm Sin B 10 42-60 (2020)
  15. Hepatic cytochromes P450: structural degrons and barcodes, posttranslational modifications and cellular adapters in the ERAD-endgame. Kim SM, Wang Y, Nabavi N, Liu Y, Correia MA. Drug Metab Rev 48 405-433 (2016)
  16. Construction of a CYP2E1-template system for prediction of the metabolism on both site and preference order. Yamazoe Y, Ito K, Yoshinari K. Drug Metab Rev 43 409-439 (2011)
  17. Adverse Effects of Perfluorooctane Sulfonate on the Liver and Relevant Mechanisms. Wang P, Liu D, Yan S, Cui J, Liang Y, Ren S. Toxics 10 265 (2022)
  18. Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles. Chamboko CR, Veldman W, Tata RB, Schoeberl B, Tastan Bishop Ö. Int J Mol Sci 24 3383 (2023)
  19. Platanosides, a Potential Botanical Drug Combination, Decrease Liver Injury Caused by Acetaminophen Overdose in Mice. Samuvel DJ, Nguyen NT, Jaeschke H, Lemasters JJ, Wang X, Choo YM, Hamann MT, Zhong Z. J Nat Prod 85 1779-1788 (2022)

Articles citing this publication (79)

  1. Genetic alterations in fatty acid transport and metabolism genes are associated with metastatic progression and poor prognosis of human cancers. Nath A, Chan C. Sci Rep 6 18669 (2016)
  2. Structural characterization of the complex between alpha-naphthoflavone and human cytochrome P450 1B1. Wang A, Savas U, Stout CD, Johnson EF. J Biol Chem 286 5736-5743 (2011)
  3. Genetic variations in human glutathione transferase enzymes: significance for pharmacology and toxicology. Josephy PD. Hum Genomics Proteomics 2010 876940 (2010)
  4. Crystal structure of a cytochrome P450 2B6 genetic variant in complex with the inhibitor 4-(4-chlorophenyl)imidazole at 2.0-A resolution. Gay SC, Shah MB, Talakad JC, Maekawa K, Roberts AG, Wilderman PR, Sun L, Yang JY, Huelga SC, Hong WX, Zhang Q, Stout CD, Halpert JR. Mol Pharmacol 77 529-538 (2010)
  5. Lettuce costunolide synthase (CYP71BL2) and its homolog (CYP71BL1) from sunflower catalyze distinct regio- and stereoselective hydroxylations in sesquiterpene lactone metabolism. Ikezawa N, Göpfert JC, Nguyen DT, Kim SU, O'Maille PE, Spring O, Ro DK. J Biol Chem 286 21601-21611 (2011)
  6. Nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone binding and access channel in human cytochrome P450 2A6 and 2A13 enzymes. DeVore NM, Scott EE. J Biol Chem 287 26576-26585 (2012)
  7. Bioactivities of berberine metabolites after transformation through CYP450 isoenzymes. Li Y, Ren G, Wang YX, Kong WJ, Yang P, Wang YM, Li YH, Yi H, Li ZR, Song DQ, Jiang JD. J Transl Med 9 62 (2011)
  8. Crystal structure of H2O2-dependent cytochrome P450SPalpha with its bound fatty acid substrate: insight into the regioselective hydroxylation of fatty acids at the alpha position. Fujishiro T, Shoji O, Nagano S, Sugimoto H, Shiro Y, Watanabe Y. J Biol Chem 286 29941-29950 (2011)
  9. Conformational adaptation of human cytochrome P450 2B6 and rabbit cytochrome P450 2B4 revealed upon binding multiple amlodipine molecules. Shah MB, Wilderman PR, Pascual J, Zhang Q, Stout CD, Halpert JR. Biochemistry 51 7225-7238 (2012)
  10. Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition. VandenBrink BM, Foti RS, Rock DA, Wienkers LC, Wahlstrom JL. Drug Metab Dispos 40 47-53 (2012)
  11. The role of ethanol metabolism in development of alcoholic steatohepatitis in the rat. Ronis MJ, Korourian S, Blackburn ML, Badeaux J, Badger TM. Alcohol 44 157-169 (2010)
  12. Oxidation of N-Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps. Chowdhury G, Calcutt MW, Guengerich FP. J Biol Chem 285 8031-8044 (2010)
  13. Schisandrol B protects against acetaminophen-induced hepatotoxicity by inhibition of CYP-mediated bioactivation and regulation of liver regeneration. Jiang Y, Fan X, Wang Y, Chen P, Zeng H, Tan H, Gonzalez FJ, Huang M, Bi H. Toxicol Sci 143 107-115 (2015)
  14. Oxidation of methyl and ethyl nitrosamines by cytochrome P450 2E1 and 2B1. Chowdhury G, Calcutt MW, Nagy LD, Guengerich FP. Biochemistry 51 9995-10007 (2012)
  15. Ubiquitin-dependent proteasomal degradation of human liver cytochrome P450 2E1: identification of sites targeted for phosphorylation and ubiquitination. Wang Y, Guan S, Acharya P, Koop DR, Liu Y, Liao M, Burlingame AL, Correia MA. J Biol Chem 286 9443-9456 (2011)
  16. Delayed Treatment With 4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice by Inhibition of c-Jun n-Terminal Kinase. Akakpo JY, Ramachandran A, Duan L, Schaich MA, Jaeschke MW, Freudenthal BD, Ding WX, Rumack BH, Jaeschke H. Toxicol Sci 170 57-68 (2019)
  17. Molecular probes of the mechanism of cytochrome P450. Oxygen traps a substrate radical intermediate. Cooper HL, Groves JT. Arch Biochem Biophys 507 111-118 (2011)
  18. Structural and functional effects of cytochrome b5 interactions with human cytochrome P450 enzymes. Bart AG, Scott EE. J Biol Chem 292 20818-20833 (2017)
  19. Human cytochrome P450 enzymes bind drugs and other substrates mainly through conformational-selection modes. Guengerich FP, Wilkey CJ, Phan TTN. J Biol Chem 294 10928-10941 (2019)
  20. Kinetic analysis of lauric acid hydroxylation by human cytochrome P450 4A11. Kim D, Cha GS, Nagy LD, Yun CH, Guengerich FP. Biochemistry 53 6161-6172 (2014)
  21. Compartmentalized effects of aging on group 2 innate lymphoid cell development and function. D'Souza SS, Shen X, Fung ITH, Ye L, Kuentzel M, Chittur SV, Furuya Y, Siebel CW, Maillard IP, Metzger DW, Yang Q. Aging Cell 18 e13019 (2019)
  22. Effect of conformational dynamics on substrate recognition and specificity as probed by the introduction of a de novo disulfide bond into cytochrome P450 2B1. Zhang H, Kenaan C, Hamdane D, Hoa GH, Hollenberg PF. J Biol Chem 284 25678-25686 (2009)
  23. Mechanism-based inactivation of human CYP2E1 by diethyldithocarbamate. Pratt-Hyatt M, Lin HL, Hollenberg PF. Drug Metab Dispos 38 2286-2292 (2010)
  24. ChannelsDB: database of biomacromolecular tunnels and pores. Pravda L, Sehnal D, Svobodová Vareková R, Navrátilová V, Toušek D, Berka K, Otyepka M, Koca J. Nucleic Acids Res 46 D399-D405 (2018)
  25. Human liver cytochrome P450 3A4 ubiquitination: molecular recognition by UBC7-gp78 autocrine motility factor receptor and UbcH5a-CHIP-Hsc70-Hsp40 E2-E3 ubiquitin ligase complexes. Wang Y, Kim SM, Trnka MJ, Liu Y, Burlingame AL, Correia MA. J Biol Chem 290 3308-3332 (2015)
  26. Aromatic hydroxylation of salicylic acid and aspirin by human cytochromes P450. Bojić M, Sedgeman CA, Nagy LD, Guengerich FP. Eur J Pharm Sci 73 49-56 (2015)
  27. Bioelectronic delivery of electrons to cytochrome P450 enzymes. Krishnan S, Schenkman JB, Rusling JF. J Phys Chem B 115 8371-8380 (2011)
  28. DNA methylation and histone acetylation changes to cytochrome P450 2E1 regulation in normal aging and impact on rates of drug metabolism in the liver. Kronfol MM, Jahr FM, Dozmorov MG, Phansalkar PS, Xie LY, Aberg KA, McRae M, Price ET, Slattum PW, Gerk PM, McClay JL. Geroscience 42 819-832 (2020)
  29. Probing small-molecule binding to cytochrome P450 2D6 and 2C9: An in silico protocol for generating toxicity alerts. Rossato G, Ernst B, Smiesko M, Spreafico M, Vedani A. ChemMedChem 5 2088-2101 (2010)
  30. Relations of oxidative stress in freshwater phytoplankton with heavy metals and polycyclic aromatic hydrocarbons. Vega-López A, Ayala-López G, Posadas-Espadas BP, Olivares-Rubio HF, Dzul-Caamal R. Comp Biochem Physiol A Mol Integr Physiol 165 498-507 (2013)
  31. Carbon-carbon bond cleavage in activation of the prodrug nabumetone. Varfaj F, Zulkifli SN, Park HG, Challinor VL, De Voss JJ, Ortiz de Montellano PR. Drug Metab Dispos 42 828-838 (2014)
  32. Discovery of TRPV1 antagonist ABT-116. Brown BS, Keddy R, Perner RJ, DiDomenico S, Koenig JR, Jinkerson TK, Hannick SM, McDonald HA, Bianchi BR, Honore P, Puttfarcken PS, Moreland RB, Marsh KC, Faltynek CR, Lee CH. Bioorg Med Chem Lett 20 3291-3294 (2010)
  33. Scanning chimeragenesis: the approach used to change the substrate selectivity of fatty acid monooxygenase CYP102A1 to that of terpene omega-hydroxylase CYP4C7. Chen CK, Berry RE, Shokhireva TKh, Murataliev MB, Zhang H, Walker FA. J Biol Inorg Chem 15 159-174 (2010)
  34. Structure of pyrazole derivatives impact their affinity, stoichiometry, and cooperative interactions for CYP2E1 complexes. Hartman JH, Bradley AM, Laddusaw RM, Perry MD, Miller GP. Arch Biochem Biophys 537 12-20 (2013)
  35. Molecular basis of the recognition of arachidonic acid by cytochrome P450 2E1 along major access tunnel. Cui YL, Zheng QC, Zhang JL, Zhang HX. Biopolymers 103 53-66 (2015)
  36. Structural basis for cooperative binding of azoles to CYP2E1 as interpreted through guided molecular dynamics simulations. Levy JW, Hartman JH, Perry MD, Miller GP. J Mol Graph Model 56 43-52 (2015)
  37. Structure and function of CYP108D1 from Novosphingobium aromaticivorans DSM12444: an aromatic hydrocarbon-binding P450 enzyme. Bell SG, Yang W, Yorke JA, Zhou W, Wang H, Harmer J, Copley R, Zhang A, Zhou R, Bartlam M, Rao Z, Wong LL. Acta Crystallogr D Biol Crystallogr 68 277-291 (2012)
  38. The role of cytochrome P450 2B6 and 2B4 substrate access channel residues predicted based on crystal structures of the amlodipine complexes. Jang HH, Davydov DR, Lee GY, Yun CH, Halpert JR. Arch Biochem Biophys 545 100-107 (2014)
  39. Campomanesia adamantium (Myrtaceae) fruits protect HEPG2 cells against carbon tetrachloride-induced toxicity. de Oliveira Fernandes T, de Ávila RI, de Moura SS, de Almeida Ribeiro G, Naves MMV, Valadares MC. Toxicol Rep 2 184-193 (2015)
  40. Control of electrochemical and ferryloxy formation kinetics of cyt P450s in polyion films by heme iron spin state and secondary structure. Krishnan S, Abeykoon A, Schenkman JB, Rusling JF. J Am Chem Soc 131 16215-16224 (2009)
  41. Cooperative effects for CYP2E1 differ between styrene and its metabolites. Hartman JH, Boysen G, Miller GP. Xenobiotica 43 755-764 (2013)
  42. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity. Bello M, Mendieta-Wejebe JE, Correa-Basurto J. Biochem Pharmacol 90 145-158 (2014)
  43. Evidence of bioactivation of halomethanes and its relation to oxidative stress response in Chirostoma riojai, an endangered fish from a polluted lake in Mexico. Vega-López A, Carrillo-Morales CI, Olivares-Rubio HF, Lilia Domínguez-López M, García-Latorre EA. Arch Environ Contam Toxicol 62 479-493 (2012)
  44. Theoretical calculations of a model of NOS indazole inhibitors: interaction of aromatic compounds with Zn-porphyrins. Elguero J, Alkorta I, Claramunt RM, López C, Sanz D, María DS. Bioorg Med Chem 17 8027-8031 (2009)
  45. Covalent modification and time-dependent inhibition of human CYP2E1 by the meta-isomer of acetaminophen. Harrelson JP, Stamper BD, Chapman JD, Goodlett DR, Nelson SD. Drug Metab Dispos 40 1460-1465 (2012)
  46. Diet-induced obesity increases the frequency of Pig-a mutant erythrocytes in male C57BL/6J mice. Wickliffe JK, Dertinger SD, Torous DK, Avlasevich SL, Simon-Friedt BR, Wilson MJ. Environ Mol Mutagen 57 668-677 (2016)
  47. Why Hepatic CYP2E1-Elevation by Itself Is Insufficient for Inciting NAFLD/NASH: Inferences from Two Genetic Knockout Mouse Models. Correia MA, Kwon D. Biology (Basel) 9 E419 (2020)
  48. Identification and characterization of miRNAs involved in cold acclimation of zebrafish ZF4 cells. Ji X, Jiang P, Luo J, Li M, Bai Y, Zhang J, Han B. PLoS One 15 e0226905 (2020)
  49. Inhibitory potency of 4-carbon alkanes and alkenes toward CYP2E1 activity. Hartman JH, Miller GP, Boysen G. Toxicology 318 51-58 (2014)
  50. Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde. Espiritu MJ, Chen J, Yadav J, Larkin M, Pelletier RD, Chan JM, Gc JB, Natesan S, Harrelson JP. Drug Metab Dispos 48 1028-1043 (2020)
  51. Pro-oxidant and antioxidant responses in the liver and kidney of wild Goodea gracilis and their relation with halomethanes bioactivation. Olivares-Rubio HF, Martínez-Torres ML, Domínguez-López ML, García-Latorre E, Vega-López A. Fish Physiol Biochem 39 1603-1617 (2013)
  52. Romidepsin (FK228) in a Mouse Model of Lipopolysaccharide-Induced Acute Kidney Injury is Associated with Down-Regulation of the CYP2E1 Gene. Cheng S, Wu T, Li Y, Huang J, Cai T. Med Sci Monit 26 e918528 (2020)
  53. Analysis of Cytochrome P450 Conserved Sequence Motifs between Helices E and H: Prediction of Critical Motifs and Residues in Enzyme Functions. Oezguen N, Kumar S. J Drug Metab Toxicol 2 1000110 (2011)
  54. Comparison of intrinsic dynamics of cytochrome p450 proteins using normal mode analysis. Dorner ME, McMunn RD, Bartholow TG, Calhoon BE, Conlon MR, Dulli JM, Fehling SC, Fisher CR, Hodgson SW, Keenan SW, Kruger AN, Mabin JW, Mazula DL, Monte CA, Olthafer A, Sexton AE, Soderholm BR, Strom AM, Hati S. Protein Sci 24 1495-1507 (2015)
  55. Exploring the structure characteristics and major channels of cytochrome P450 2A6, 2A13, and 2E1 with pilocarpine. Fan JR, Li H, Zhang HX, Zheng QC. Biopolymers 109 e23108 (2018)
  56. Functioning of Microsomal Cytochrome P450s: Murburn Concept Explains the Metabolism of Xenobiotics in Hepatocytes. Manoj KM, Parashar A, Gade SK, Venkatachalam A. Front Pharmacol 7 161 (2016)
  57. Identification of a Shared Cytochrome p4502E1 Epitope Found in Anesthetic Drug-Induced and Viral Hepatitis. McCarthy EK, Vakos A, Cottagiri M, Mantilla JJ, Santhanam L, Thomas DL, Amzel LM, Rose NR, Njoku DB. mSphere 3 e00453-18 (2018)
  58. Immune-Deficient Pfp/Rag2-/- Mice Featured Higher Adipose Tissue Mass and Liver Lipid Accumulation with Growing Age than Wildtype C57BL/6N Mice. Winkler S, Hempel M, Hsu MJ, Gericke M, Kühne H, Brückner S, Erler S, Burkhardt R, Christ B. Cells 8 E775 (2019)
  59. Pro-oxidant and antioxidant response elicited by CH2Cl2, CHCl3 and BrCHCl2 in Goodea gracilis using non-invasive methods. Dzul-Caamal R, Olivares-Rubio HF, López-Tapia P, Vega-López A. Comp Biochem Physiol A Mol Integr Physiol 165 515-527 (2013)
  60. Type II ligands as chemical auxiliaries to favor enzymatic transformations by P450 2E1. Ménard A, Fabra C, Huang Y, Auclair K. Chembiochem 13 2527-2536 (2012)
  61. Comparative phytotoxicity of Rac-metolachlor and S-metolachlor on rice seedlings. Liu HJ, Xiong MY, Tian BL. J Environ Sci Health B 47 410-419 (2012)
  62. Cytochrome P450 CYP2E1 Suppression Ameliorates Cerebral Ischemia Reperfusion Injury. Yu J, Zhu H, Kindy MS, Taheri S. Antioxidants (Basel) 10 52 (2021)
  63. Diets with corn oil and/or low protein increase acute acetaminophen hepatotoxicity compared to diets with beef tallow in a rat model. Hwang J. Nutr Res Pract 3 95-101 (2009)
  64. Mechanism of Chronic Kidney Disease Progression and Novel Biomarkers: A Metabolomic Analysis of Experimental Glomerulonephritis. Han KH, Kim B, Ji SC, Kang HG, Cheong HI, Cho JY, Ha IS. Metabolites 10 E169 (2020)
  65. A Comparison of the In Vitro Inhibitory Effects of Thelephoric Acid and SKF-525A on Human Cytochrome P450 Activity. Song M, Do H, Kwon OK, Yang EJ, Bae JS, Jeong TC, Song KS, Lee S. Biomol Ther (Seoul) 22 155-160 (2014)
  66. Combination treatment of epilepsy with ketogenic diet and concurrent pharmacological inhibition of cytochrome P450 2E1. Palmer M. Med Hypotheses 80 481-485 (2013)
  67. Murburn Concept: A Molecular Explanation for Hormetic and Idiosyncratic Dose Responses. Parashar A, Gideon DA, Manoj KM. Dose Response 16 1559325818774421 (2018)
  68. New amino acid-Schiff base derived from s-allyl cysteine and methionine alleviates carbon tetrachloride-induced liver dysfunction. Ratha P, Chitra L, Ancy I, Kumaradhas P, Palvannan T. Biochimie 138 70-81 (2017)
  69. Physiologically Based Pharmacokinetic (PBPK) Modeling of Metabolic Pathways of Bromochloromethane in Rats. Cuello WS, Janes TA, Jessee JM, Venecek MA, Sawyer ME, Eklund CR, Evans MV. J Toxicol 2012 629781 (2012)
  70. Trihalomethanes in liver pathology: Mitochondrial dysfunction and oxidative stress in the mouse. Faustino-Rocha AI, Rodrigues D, da Costa RG, Diniz C, Aragão S, Talhada D, Botelho M, Botelho M, Colaço A, Pires MJ, Peixoto F, Oliveira PA. Environ Toxicol 31 1009-1016 (2016)
  71. π-π Stacking mediated drug-drug interactions in human CYP2E1. Liu Y, Liu BY, Hao P, Li X, Li YX, Wang JF. Proteins 81 945-954 (2013)
  72. Analysis of Species-Selectivity of Human, Mouse and Rat Cytochrome P450 1A and 2B Subfamily Enzymes using Molecular Modeling, Docking and Dynamics Simulations. Karthikeyan BS, Suvaithenamudhan S, Akbarsha MA, Parthasarathy S. Cell Biochem Biophys 76 91-110 (2018)
  73. Burn after feeding. An old uncoupler of oxidative phosphorylation is redesigned for the treatment of nonalcoholic fatty liver disease. Fromenty B. Clin Res Hepatol Gastroenterol 38 545-549 (2014)
  74. Comparative analysis of binding affinities between styrene and mammalian CYP2E1 by bioinformatics approaches. Wu B, Sun J, Cheng SP, Gu JD, Li AM, Zhang XX. Ecotoxicology 20 1041-1046 (2011)
  75. Crosstalk between CYP2E1 and PPARα substrates and agonists modulate adipose browning and obesity. Zhang Y, Yan T, Wang T, Liu X, Hamada K, Sun D, Sun Y, Yang Y, Wang J, Takahashi S, Wang Q, Krausz KW, Jiang C, Xie C, Yang X, Gonzalez FJ. Acta Pharm Sin B 12 2224-2238 (2022)
  76. Fennel and raspberry leaf as possible inhibitors of acetaminophen oxidation. Langhammer AJ, Nilsen OG. Phytother Res 28 1573-1576 (2014)
  77. Galeon: A Biologically Active Molecule with In Silico Metabolite Prediction, In Vitro Metabolic Profiling in Rat Liver Microsomes, and In Silico Binding Mechanisms with CYP450 Isoforms. Rahman AFMM, Yin W, Kadi AA, Jahng Y. Molecules 25 E5903 (2020)
  78. Genetic polymorphism in cytochrome P450 2E1 and alcoholic pancreatitis sus-ceptibility: a meta-analysis. Wu C, Wu D, Liu Y, Zhong Y. Hippokratia 22 60-67 (2018)
  79. Repeated administration of ethambutol in therapeutic dose causes testes alteration and spermatogenesis disruption in Wistar rats. Shayakhmetova GM, Bondarenko LB, Voronina AK, Matvienko AV, Kitam V, Kovalenko VM. Hum Exp Toxicol 36 520-533 (2017)